Expression pattern of perilipins in human brain during aging and in Alzheimer's disease by Conte, Maria et al.
OR I G I N A L A R T I C L E
Expression pattern of perilipins in human brain during aging
and in Alzheimer’s disease
Maria Conte1,2 | Valentina Medici3 | Davide Malagoli4 | Antonio Chiariello1 |
Alice Cirrincione3 | Annalisa Davin3 | Maia Chikhladze3,5 | Francesco Vasuri6 |
Giuseppe Legname7 | Isidre Ferrer8,9,10 | Silvia Vanni11 |
Gabriella Marcon12,13 | Tino Emanuele Poloni3 | Antonio Guaita3 |
Claudio Franceschi14 | Stefano Salvioli1,2
1Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
2Interdepartmental Centre “Alma Mater Research Institute on Global Challenges and Climate Change (Alma Climate)”, University of Bologna, Bologna, Italy
3Department of Neurology and Neuropathology, Golgi-Cenci Foundation, Milan, Italy
4Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
5Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy
6Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, Bologna, Italy
7Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy
8Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, Barcelona, Spain
9Bellvitge Biomedical Research Institute-IDIBELL, Department of Pathologic Anatomy, Bellvitge University Hospital, Barcelona, Spain
10Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, L’Hospilatet del Llobregat, Barcelona,
Spain
11Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
12DAME, University of Udine, Udine, Italy
13Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy
14Institute of Information Technologies, Mathematics and Mechanics, Lobachevsky University, Nizhniy Novgorod, Russia
Correspondence
Maria Conte, Department of Experimental,
Diagnostic and Specialty Medicine (DIMES),
University of Bologna, Bologna, Italy.
Email: m.conte@unibo.it
Funding information
Ministry of Science and Higher Education at
the Lobachevsky State University of Nizhny
Novgorod, Grant/Award Number:
075-15-2019-871; Roberto and Cornelia
Pallotti Legacy for Cancer Research
Abstract
Aims: Perilipins are conserved proteins that decorate intracellular lipid droplets and are
essential for lipid metabolism. To date, there is limited knowledge on their expression in
human brain or their involvement in brain aging and neurodegeneration. The aim of this
study was to characterise the expression levels of perilipins (Plin1–Plin5) in different
cerebral areas from subjects of different age, with or without signs of
neurodegeneration.
Methods: We performed real-time RT-PCR, western blotting, immunohistochemistry
and confocal microscopy analyses in autoptic brain samples of frontal and temporal
cortex, cerebellum and hippocampus from subjects ranging from 33 to 104 years of age,
with or without histological signs of neurodegeneration. To test the possible relationship
between Plins and inflammation, correlation analysis with IL-6 expression was also
performed.
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Results: Plin2, Plin3 and Plin5, but not Plin1 and Plin4, are expressed in the considered
brain areas with different intensities. Plin2 appears to be expressed more in grey matter,
particularly in neurons in all the areas analysed, whereas Plin3 and Plin5 appear to be
expressed more in white matter. Plin3 seems to be expressed more in astrocytes. Only
Plin2 expression is higher in old subjects and patients with early tauopathy or
Alzheimer’s disease and is associated with IL-6 expression.
Conclusions: Perilipins are expressed in human brain but only Plin2 appears to be
modulated with age and neurodegeneration and linked to an inflammatory state. We
propose that the accumulation of lipid droplets decorated with Plin2 occurs during brain
aging and that this accumulation may be an early marker and initial step of inflammation
and neurodegeneration.
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INTRODUCTION
Aging is considered the major risk factor for the development of neu-
rodegenerative diseases, such as Alzheimer’s disease (AD). Neu-
rodegeneration is due to a progressive loss of neurons and
connections, leading to atrophy of both grey and white matter, most
prominently in the temporal and frontal lobes [1, 2]. However,
although several age-associated neuronal changes have been clarified,
many aspects of brain aging remain controversial and unclear. Recent
evidence suggests that brain aging is characterised by chronic alter-
ations of energy metabolism and in particular lipid metabolism [3].
The dysregulation of lipid metabolism in the brain leads to the accu-
mulation of lipids including toxic ones, such as long-chain ceramides
[4–6], and to the formation of lipid-laden cells (LLCs) [7]. This accumu-
lation, together with the decline of omega-3 fatty acids [8], partici-
pates in the induction of age-related neuroinflammatory processes,
closely associated with the onset of neurodegenerative disorders
[9, 10]. Intracellular lipid storage occurs within organelles, called lipid
droplets (LDs). During aging, the content and composition of LDs may
vary, leading to an increase of ectopic lipid deposition in several
nonadipose tissues (i.e., liver, skeletal muscle and pancreas) [11–13].
Though LDs were originally considered only as fat depots, recent
evidence demonstrates that they are dynamic organelles involved in
numerous cellular processes [14, 15]. Despite the fact that lipids are
crucial components of the brain, so far, little is known about the func-
tion of LDs in this organ, especially in the context of neurodegenera-
tive diseases [16].
LDs are characterised by a core of neutral lipids, containing cho-
lesterol esters and triglycerides, and surrounded by a monolayer of
phospholipids associated with several proteins involved in lipid
metabolism. Among these proteins, the most abundant and well
characterised are perilipins (Plins). Plins belong to a family of five evo-
lutionary conserved proteins (called Plin1 to Plin5), known as the PAT
protein family [13, 17, 18]. Plins are involved in different cellular pro-
cesses, such as LD formation, trafficking and turnover. Each Plin dis-
plays a specific expression pattern; for example, Plin1 is expressed
only in adipose tissue, Plin2 and Plin3 are ubiquitously expressed in
nonadipose tissues, whereas Plin5 is particularly expressed in meta-
bolic tissues, such as skeletal muscle and brown adipose tissue [13].
Moreover, because Plin2 is always associated to the surface of LDs, it
is considered as a marker of LDs content [13, 19–21]. In the last few
years, Plins received considerable attention because they are essential
for the normal physiology of cells. Moreover, the differential expres-
sion of these proteins is associated with alteration in lipid metabolism,
causing several metabolic disorders and age-related diseases [22, 23].
We have reported that high levels of Plin2, in both humans and mice,
are associated with muscle atrophy and sarcopenia [24–26]. In addi-
tion, several lines of evidence from other laboratories indicate that
high levels of Plin2 are associated with fatty liver disease, atheroscle-
rosis, obesity, cardiovascular diseases and diabetes, whereas the
downregulation or knockout of Plin2 prevents or mitigates these
pathologies [13, 27–29]. Alteration of Plins has been reported also in
several tumours, including liposarcomas, melanoma, renal cell carci-
noma, pancreatic ductal adenocarcinoma and breast cancer [13].
To date, little is known about the expression of Plins in human
brain and their possible changes during aging or in neurodegenerative
diseases. In this study, we aimed to characterise the expression levels
Key points
• Plin2, Plin3 and Plin5, but not Plin1 and Plin4, are
expressed in human brain with differences at the level of
areas as well as white and grey matter and brain cell
types.
• Plin2 appears to be expressed in neurons and the only
one affected by age and neurodegenerative diseases.
• Plin2 seems to be associated with IL-6 expression,
suggesting a possible connection between accumulation
of Plin2-positive lipid droplets and neuroinflammation.
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of Plins in different cerebral areas (frontal and temporal cortex, cere-
bellum and hippocampus) from subjects of different age (from 33 to
104 years), with or without signs of neurodegeneration, such as early
tauopathy (ET) or AD.
METHODS
Human brain samples
Fifty autopsy human brain samples from subjects in the age range 33–
104 years, with or without (controls) signs of neurodegeneration,
were used for this study. Most of the samples were provided by dif-
ferent brain banks: Abbiategrasso Brain Bank at Golgi Cenci Founda-
tion (Milan, Italy), MRC Edinburgh Brain Bank, Institute of
Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank, Barcelona,
Spain). Moreover, 11 samples were collected in the framework of the
European Project PROTEOMAGE (grant agreement: FP6-518230). All
the samples were collected according to the guidelines of the local
ethical committees. Table S1 reports information about all the sam-
ples, as also below described:
1. Abbiategrasso Brain Bank at Golgi Cenci Foundation. Eighteen
samples were used: (i) one control subject without signs of neu-
rodegeneration; (ii) five subjects with a neuropathological picture
of low AD, including three without cognitive impairment, one with
mild neurocognitive disorder (NCD) and one with major NCD;
(iii) one subject with age-related TAU pathology and major NCD
and (iv) 11 subjects with a neuropathological picture of high/inter-
mediate AD and a clinical diagnosis of major NCD. The classifica-
tion into ‘low’, ‘intermediate’ and ‘high’ AD was made according
to the NIA-Alzheimer’s Association guidelines for neuropathologi-
cal assessment of AD, using the ABC score (a combination of: Aβ
plaques diffusion stage, Braak stage for TAUopathy and CERAD
semiquantitative grading for neuritic plaques) [30]. Low AD pathol-
ogy is defined by the presence of a Braak stages I–II (B1), in the
presence of any amyloid stage, or even by higher Braak stages if
the presence of amyloid and neuritic plaques is slight (A1, C1),
whereas intermediate and high AD is defined by the concomitance
of more severe pathology in both amyloid and Braak stages. From
all these samples, the following brain areas were studied: frontal
and temporal cortex, cerebellum and hippocampus. All donors
underwent an extensive multidimensional assessment including
clinical diagnosis, neuropsychological, biological and social evalua-
tions, as previously described [31, 32]. The study protocol received
approval from the Ethical Committee of Pavia University
(Committee report 3/2009). All subjects joining the donation
signed a specific consent form. In case a person was not deemed
competent to sign, authorisation from the legal guardian or next-
of-kin (NOK) was required. The research was performed under the
supervision of the Federazione Alzheimer Italia.
2. MRC Edinburgh Brain Bank. Nine samples of frontal cortex from
subjects without neurodegeneration, who died from pathologies
not affecting the brain and lacking any neurological sign (controls).
The use of these samples was covered by ethical approval from
the East of Scotland Research Ethics Service REC 1 (reference
number 16/ES/0084). Informed consent for the research use of
autopsy tissue was obtained from the relatives of the deceased
whenever necessary.
3. Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank). Ten
samples of frontal cortex from subjects with signs of ET, Braak
stages I–II without βA deposition. Samples were obtained follow-
ing the guidelines of Spanish legislation (Real Decreto 1716/2011)
and the approval of the local ethics committee.
4. PROTEOMAGE. Eleven samples of frontal cortex from subjects of
different age (33–103 years), died from pathologies not affecting
the brain and lacking any neurological sign (controls). Among these
controls, four were affected by hemiparesis; therefore, the samples
were obtained from the unaffected hemisphere; two samples of
frontal cortex were from centenarians (103 years old) affected by
cognitive impairment and who died of old age. Given the difficulty
to make a proper aetiological diagnosis of dementia during life,
post-mortem neuropathological studies were performed. These
samples were available in the biobank of the Immunology Lab at
Bologna University (S. Salvioli) and were received from partners of
the European Project PROTEOMAGE.
DFs culture and treatment
Primary dermal fibroblast (DF) cultures were obtained from biopsies
of sun-protected areas (forearm or thigh) from five subjects without
neurodegenerative disorders (controls: two young of 34 years, three
old of 74 years), two AD patients (83 and 85 years) and three non-AD
centenarians (100, 104 and 107 years). DFs from controls and two
centenarians were available at the biobank of the Salvioli’s laboratory,
and those from AD patients and one centenarian came from the
Abbiategrasso Golgi Cenci Foundation. In these latter subjects,
the biopsy was performed at an average time of approximately 8 h
post-mortem. DFs were cultured in DMEM supplemented with 10%
heat-inactivated fetal calf serum (FCS), penicillin (100 units/ml), strep-
tomycin (100 g/ml) and 2 mM L-glutamine (all from Sigma) and kept in
an incubator at 5% CO2 humidified atmosphere at 37C. DFs from the
sixth to 14th passage were used for the experiments. For the experi-
ments, the cells were reseeded (125,000 cells/cm2) in FCS-
supplemented medium in the presence or absence of 1 mM metfor-
min (Sigma). Cells were collected after 48 h of treatment.
Tissue preparation, light microscopy and IHC
Neuropathological characterisation of samples was carried out on for-
malin fixed slices, embedded in paraffin and cut in 8-μm-thick serial
sections. The sections were stained with haematoxylin and eosin,
cresyl violet, luxol fast blue and Gallyas to evaluate vascular, architec-
tural and structural tissue abnormalities, myelin loss and neuritic
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plaques. For immunohistochemical analysis, NeuN and GFAP were
used to evaluate neuronal and glial compartments. AT8, 4G8,
α-synuclein and TDP43 antibodies were used to assess all the main
proteinopathies [32].
Selected sections were deparaffinised and pretreated with 3%
H2O2 in PBS to neutralise endogenous peroxidase activity, unmasked
using four 5-min cycles in citrate buffer, incubated with 5% normal
goat serum for 30 min to mask non-specific adsorption sites and then
incubated over night at room temperature with the primary antibodies
(Table S2). On the day after, the sections were rinsed in PBS and incu-
bated with secondary antibody (EnVision+ System-HRP Labelled
Polymer) for 1 h at room temperature, and the antigen–antibody reac-
tion was revealed using diaminobenzidine tetrahydrochloride (DAB+
Substrate Chromogen System, Dako) as chromogen. Control experi-
ments (primary antibodies omitted) showed the absence of non-
specific binding. The sections from all subjects were immunostained in
a single batch in order to minimise variability and allow reliable com-
parison of the data obtained from the different cases.
Immunofluorescence and confocal microscopy
Selected paraffin sections were incubated overnight in a mixture of
primary monoclonal and polyclonal antibodies (NeuN/Plins, GFAP/
Plins, Olig2/Plins and TMEM119/Plins) and subsequently incubated in
a mixture of the corresponding secondary antibodies (GAM cy2/GAR
cy3 and DAR cy2/GAR cy3). NeuN was used as marker for neurons,
GFAP for astrocytes, Olig2 for oligodendrocytes and TMEM119 for
microglia.
All slides were examined with Nikon Eclipse Ni (Nikon) and
images obtained with NIS Elements AR software (Nikon). These
images were used to calculate the percentage of neurons and astro-
cytes expressing Plin2 and Plin3, respectively.
Then, the slides were examined with a Leica TCS-SP8 Laser
Scanning Confocal Microscope (Leica Microsystems), equipped with
blue COH (405 nm/25 mW) and white WWL (470 and 650 nm) lasers
and managed by LASX Core Edition 3.3.0 software. Confocal
high-resolution images were obtained in sequential scan mode, in
order to exclude dye emission interference during image acquisition.
For each dye, a specific panel of parameters was set before sequential
image acquisition. Acquisition parameters were maintained for all the
sessions in order to allow a fine comparison between signals from
different slides. Images were processed with the open-source Fiji
package [33].
RNA extractions and gene expression analysis
Total RNA was isolated from 50–100 mg of frozen (80C) frontal
cortex samples. The tissue was homogenised with Stainless Steel
Beads 5 mm in Tissue Lyser II (Qiagen), in TRIzol reagent (Invitrogen)
following the manufacturer’s instructions. RNA was extracted with
PureLink RNA Mini Kit (Life Technologies), and on-column DNA
digestion was performed using PureLink DNase Set (Life Technolo-
gies). RNA was checked for concentration and purity on a NanoDrop
2000 spectrophotometer (Thermo Scientific), whereas RNA integrity
was analysed using 2100 Bioanalyzer (Agilent Technologies). Samples
with an RNA integrity number (RIN) ≥ 4 were included in the gene
expression analysis.
Total RNA from DFs was isolated by using the AllPrep Universal
Kit (Qiagen), according to the manufacturer’s instructions.
cDNA was synthesised using iScript™ cDNA Synthesis Kit (Bio-
Rad) according to the manufacturer’s instructions. Real-time RT-PCR
was performed with iTaq™ Universal SYBR Green Supermix (Bio-Rad)
and Rotor gene Q 6000 system (Qiagen). Six housekeeping genes
(18S rRNA, βActin, glyceraldehyde-3-phosphate dehydrogenase
[GAPDH], glucuronidase β, ribosomal protein large P0 and phospho-
glycerate kinase 1 [PGK1]) were tested for their suitability as control
genes. GAPDH and PGK1 were then chosen as reference genes, as
they gave the more stable results, and all data were then normalised
to these genes. The relative expression ratio was calculated using the
2ΔΔCT method. Expression analysis of the following genes was
undertaken: MAP2, Plin1, Plin2, Plin3, Plin4 and Plin5. All oligonucleo-
tide predesigned primers were from Bio-Rad (primer information are
available at website www.bio-rad.com/PrimePCR).
Protein extraction and WB
Protein extracts were obtained from 30–100 mg of frozen (80C)
samples of different areas (frontal and temporal cortex, cerebellum
and hippocampus). Samples were lysed in lysis buffer consisting of
urea 8 M, CHAPS 4%, DTT 65 mM, Tris 40 mM, phosphatase
and protease inhibitors (Sigma). Total protein extract was quantified
by Bradford’s method and stored at 80C until analysis.
Twenty micrograms of the total protein was separated on a 12%
SDS-polyacrilamide gel, transferred to a nitrocellulose membrane
(Trans-Blot Transfer Medium, Bio-Rad) and immunoblotted with
primary antibodies (Table S2); 1:3000 GAPDH antibody was used as a
loading control. Densitometry analysis of bands was performed using
ImageJ software.
Statistical analysis
All statistical tests used are reported in each figure legend. The com-
parison of different brain areas as far as Plins expression, as well as
the comparison by age group, was performed by using the Kruskal–
Wallis test, whereas the comparison between adult and old subjects
was performed by using the Mann–Whitney test, because these data
analysed did not follow a normal distribution. The Student’s t test was
used to compare control subjects versus ET patients and DFs
untreated versus treated with metformin. The analysis of the data
obtained from the comparison among AD patients (low, intermediate
and high) and centenarians was performed by the one-way ANOVA.
The Bonferroni correction was applied. The relationships between
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Plins and IL-6 expression levels were calculated by the Spearman rank
correlation test and regression analysis. Significance was accepted as
p < 0.05. Data are expressed as mean  SE or mean  SD. All data
were analysed using the SPSS 23.0 for Windows software.
RESULTS
Plin2, Plin3 and Plin5 proteins are expressed in
brain areas
We characterised the protein expression of Plins by western blotting
(WB) in different areas of the brain (cerebellum, C; temporal cortex, T;
frontal cortex, F; hippocampus, H) from nine control subjects (age
range 71–95 years). We observed that only Plin2, Plin3 and Plin5
were expressed in the brain, whereas Plin1 and Plin4 were
undetectable by WB in all the investigated areas. Figure 1A shows the
results for three representative subjects. Moreover, Plin2 was
expressed at significantly lower levels in the cerebellum with respect
to other areas (Figure 1B), Plin3 followed a similar trend, but a signifi-
cant difference in the expression level was found only between cere-
bellum and hippocampus (Figure 1C). Plin5 appeared equally
expressed in all the considered areas (Figure 1D). To investigate the
topographical distribution of Plin2, Plin3 and Plin5, an immunohisto-
chemistry (IHC) analysis was performed. Plin2 immunoreactivity
showed a diffuse staining of mild intensity (Figure 2A–D). All areas
showed a similar Plin2 staining level; however, frontal and temporal
cortex exhibited a slightly more intense staining of Plin2 with respect
F I GU R E 1 Western blotting (WB) analysis of Plins protein expression in different brain areas. (A) Representative immunoblotting image of
Plin1, Plin2, Plin3, Plin4 and Plin5 in cerebellum (C), temporal cortex (T), frontal cortex (F) and hippocampus (H) from three representative old
subjects (75, 80 and 82 years) without neurodegenerative diseases. (B–D) Relative protein expression levels of (B) Plin2, (C) Plin3 and (D) Plin5
in C, T, F and H areas from 10 old subjects without neurodegenerative diseases (control). The bars represent mean  SE. Kruskal–Wallis and
Bonferroni tests were applied. WB quantification of Plins expression was performed using ImageJ software and normalised to GAPDH protein
expression. Control (ctr) tissues, such as skeletal muscle (sm) and adipose tissue (ad), are used as internal controls
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to the other areas (Figure 2, B and C vs A and D). It is notable that in
the cortex, Plin2 immunostaining had a fascicular appearance, stron-
ger in grey than in white matter (Figure 2B,C), particularly, in neuronal
cytoplasm and in proximal neuronal fibres, both in the apical dendrites
and in the axons (Figure 2C0,D0). Plin3 and Plin5 showed intense
expression in all the areas examined, with more evident staining in the
glial white matter compartment (Figure 2E–L). The difference
between grey and white matter immunostaining intensity was more
evident for Plin3 than Plin5 (Figure 2, F vs J and G vs K). Moreover,
Plin3 staining appeared more evident in astrocytes (Figure 2E0–G0),
whereas Plin5 staining seemed to highlight the fibres in their axonal
or myelin component (Figure 2I0–L0) and also marked some glial cells
(Figure 2J0).
IHC analysis for Plin1 and Plin4 confirmed the almost total
absence of these proteins, as observed with WB. Very weak expres-
sion was present only in some neurons of the cortical grey matter
(Figure S1).
In order to confirm that in grey matter Plin2 is expressed preva-
lently in neurons and Plin3 in astrocytes, we performed a double
immunofluorescence labelling with antibodies specific for NeuN
(neurons), GFAP (astrocytes), Plin2 and Plin3. Confocal microscopy
analysis confirmed that Plin2 is expressed within NeuN+ cells
(Figure 3A–C), whereas Plin3 is expressed within GFAP+ ones
(Figure 3D–F). In contrast, Plin2 and Plin3 did not localise within
GFAP+ and NeuN+ cells respectively (data not shown). The percent-
age of neurons positive for Plin2 was 66.5% (Figure S2A–D), whereas
the percentage of astrocytes positive for Plin3 was 87.1%
(Figure S2E–H), with apparently no difference between old and AD
subjects (data not shown).
Because Plin3 was expressed primarily in white matter, we evalu-
ated whether it was also expressed in oligodendrocytes. We tested
the possible expression of Plin3 and Plin5 within Olig2+ cells, a
marker for oligodendrocytes. Confocal microscopy indicated that
Plin3 is not expressed in Olig2+ cells (Figure S3A–C), even though we
cannot totally rule out that some Plin3+ oligodendrocytes do exist. In
contrast, Olig2+ cells were positive for Plin5, suggesting that oligo-
dendrocytes preferentially express Plin5 rather than Plin3
(Figure S3D–F).
F I GU R E 2 Immunohistochemical analysis
of Plins in different brain areas. Localisation
and distribution of (A–D0) Plin2, (E–H) Plin3
and (I–L0) Plin5 in sections from autoptic
human tissues of (A,E,E0,I,I0) cerebellum, (B,F,
F0 ,J,J0) temporal cerebral cortex, (C,C0,G,G0,K,
K0) frontal cerebral cortex and (D,D0,H,L,L0)
hippocampus. Plin2 immunoreactivity is
evident (B,C) in the grey matter of cerebral
cortex, (D) in the hippocampus and, to a lesser
extent, (A) in the white matter of the
cerebellum. Neuronal proximal fibres and
some of the cytoplasm of neurons are clearly
positive (C0 , D0). Note the intense Plin3 and
Plin5 labelling, particularly evident in the
white matter of the (E,I) cerebellum, (F, G, J, K)
cerebral cortex and (H–L) hippocampus.
Representative Plin3-positive neuropil and
astrocytes around (E0) Purkinje cells, in (F0)
grey and (G0) white matter of cerebral cortex
are shown at higher magnification. Strong
Plin5 labelling (I,I0 ,J,K,K0 ,L,L0) outlines axonal
fibres in all areas and (J0) marks some glial
cells. Scale bars: (A,D0 ,E0 ,F0 ,G0 ,I0,J0 ,K0,L0) 58 μm;
(B,C,J,K) 198 μm; (D–L) 460 μm; (C0) 50 μm
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Finally, because it was recently reported that Plin2 is expressed in
microglia of human and mouse brain [34], we checked the expression
of Plin2 within cells positive for TMEM119, a marker of resident
microglia [35]. We observed Plin2 expression in a few
TMEM119-positive cells in the frontal cortex (Figure 3G–I).
Plin2 and Plin3 are expressed at high levels in old
subjects
We then sought to determine whether the expression of Plins is mod-
ulated by age. WB analysis of Plins was conducted in samples from
eight subjects of different age (from 33 to 82 years) without signs of
neurodegeneration, subdivided in adult (n = 3) and old (n = 5) sub-
jects. The results indicated that Plin2 was expressed more in old
subjects in all the areas considered (Figure 4A–D), although it was not
possible to determine whether the higher level of Plin2 expression
observed with old age was due to an increased number of neurons
expressing Plin2, an increased expression per neuron, or both. Also,
Plin3 appeared to be expressed slightly more in the elderly; however,
the difference was never statistically significant (Figure 4A–D). Plin5
was expressed similarly in all subjects (Figure 4A–D). Furthermore, a
partial investigation into exceptional longevity was possible due to
the availability of frontal cortex from three centenarians. A compari-
son of Plin2, Plin3 and Plin5 protein expression with three adult and
four old subjects was then performed. Samples from centenarians did
not differ from those of old subjects. Also, in these cases, only Plin2,
Plin3 and Plin5 were detectable, and Plin2 expression was similar to
that of old subjects and higher with respect to that of adults. Plin3
and Plin5 were expressed to a similar extent in all the three age
groups (Figure S4A–D). As expected, Plin1 and Plin4 were
undetectable (data not shown).
Plin2 is expressed more in subjects with
neurodegenerative diseases
Because age is the most important risk factor for neurodegeneration,
in the light of the above-described results, we investigated the
expression levels of Plins in samples from patients with signs of
F I GU R E 3 Confocal microscopy analysis.
Plin2 and Plin3 colocalisation with neuronal,
astrocyte and microglia markers (NeuN, GFAP
and TMEM119, respectively). (A–C) NeuN
(green), Plin2 (red) and merge in neurons. (D–F)
GFAP (green), Plin3 (red) and merge in
astrocytes. (G–I) TMEM119 (green), Plin2 (red)
and merge in microglia. Scale bars: (A–C)
10.5 μm; (D–F) 15 μm; (G–I) 10 μm
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neurodegeneration. We first compared the transcript levels of Plins in
samples of frontal cortex from 10 patients with ET to nine age-
matched controls without neurodegenerative diseases, in order to
identify possible different expression levels of Plins at the very early
stages of the neuropathology. At variance with protein expression,
the transcripts of Plin1 and Plin4 were detectable in these samples.
Only the expression level of Plin2, but not that of all the other Plins,
appeared higher in ET patients with respect to controls (Figure 5A).
Because Plin2 was localised in neurons according to the IHC analysis,
and because neurodegeneration is characterised by a decrease in the
number of neurons, this result could appear paradoxical. In fact, in ET
samples, the expression level of MAP2, a neuron-specific gene, was
decreased with respect to controls, as expected (Figure 5B, left panel),
and when Plin2 expression was normalised with respect to MAP2, the
difference to controls was even more significant (Figure 5B, right
panel). This result suggests that neurons from ET samples might be
characterised by a very high level of Plin2 expression. To further sup-
port this hypothesis, we performed IHC of Plin2 in brain samples from
ET patients (Braak stages I–II, without relevant amyloid load). Plin2
immunoreactivity showed a diffuse and intense staining of pyramidal
neurons (Figure S5).
Real-time analysis was also performed in frontal cortex samples
from patients with different severity of AD (low, intermediate and
high, based on neuropathological diagnosis [30]) and from centenar-
ians. As expected, the expression of MAP2 decreased with increasing
severity of AD and with age (Figure 5C, left panel). We observed that
the Plin2/MAP2 ratio is higher in patients with high AD with respect
to patients with low and intermediate AD (Figure 5C, right panel).
Notably, the Plin2/MAP2 ratio in centenarians was strikingly lower
compared with high or intermediate AD patients and more similar to
that of low AD patients, despite the low expression of MAP2. This
suggests that, despite the decrease in number, the neurons of cente-
narians are different from those of AD patients in terms of Plin2
expression (and therefore lipid accumulation) and more similar to
those of 70- to 80-year-old people with little neurodegeneration. This
result agrees with WB analysis showing that centenarians have levels
of Plin2 protein expression that are similar to those of old people
(Figure S2).
F I GU R E 4 Western blotting (WB) analysis of Plins protein in different brain areas from control subjects of different age. (A–D)
Representative immunoblotting image of Plin2, Plin3, Plin5 and relative protein expression of Plin2 and Plin3 in (A) frontal cortex, (B) temporal
cortex, (C) hippocampus and (D) cerebellum. The bars represent mean  SE. Mann–Whitney test was applied. WB quantification of Plins
expression performed using ImageJ software and normalised to GAPDH protein expression
8 CONTE ET AL.
Because Plin2 appears to be expressed mainly in grey matter neu-
rons, according to IHC, in order to be sure that the result from AD
samples was not due to randomly different proportions of grey and
white matter in the samples from which the RNA was extracted, we
explored the protein expression of Plins in samples of grey and white
matter of frontal cortex from AD patients. In agreement with IHC ana-
lyses, Plin2 was expressed more in grey matter, whereas Plin3 was
expressed more in white matter (Figure 5D). Moreover, Plin2 expres-
sion was higher in grey matter samples of AD patients with respect to
the control sample (Figure 5D), confirming the results from transcript
analysis. No significant difference was found for Plin5 (Figure 5D),
whereas, at variance with the transcript levels, Plin1 and Plin4 were
undetectable in all subjects analysed (data not shown). This discrep-
ancy between transcription and protein levels is not unusual for Plins,
as already reported in other studies performed on different cell types,
such as adipocytes, suggesting the existence of a post-translational
regulation mediated by the ubiquitin/proteasome pathway [36, 37].
Plin2 expression correlates with IL-6
Recent evidence indicates that Plin2 can be considered a marker not
only of LDs but also of inflammation in the brain [16, 34, 38]. To
explore this hypothesis, we analysed transcript levels of Plins and
IL-6, a pro-inflammatory cytokine involved in neurodegenerative dis-
orders such as AD [39]. Spearman correlation analysis (Table 1) and
linear regression analysis (Figure 6A) performed in frontal cortex sam-
ples from nine control subjects, 10 ET patients, 15 AD patients and
three centenarians, indicated that only Plin2 was positively and signifi-
cantly correlated with IL-6, confirming that Plin2 is related to
F I GU R E 5 Plins mRNA and protein
expression analysis in early tauopathy
(ET) or Alzheimer’s disease (AD) patients.
(A) Relative transcript levels of Plin1,
Plin2, Plin3, Plin4 and Plin5 in frontal
cortex samples from 10 patients with ET
and nine age-matched controls.
(B) Relative transcript levels of MAP2 (left
panel) and Plin2/MAP2 ratio (right panel)
of the samples as in (A). (C) Relative
transcript levels of MAP2 (left panel) and
Plin2/MAP2 ratio (right panel) of patients
with low, intermediate and high AD and
centenarians. (D) Immunoblotting image
of Plin2, Plin3 and Plin5 in grey (gm) and
white (wm) matter from frontal cortex of
AD patients as compared with one age-
matched control. The bars represent
mean  SE. Student’s t and one-way
ANOVA tests were applied
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inflammatory phenomena and suggesting that Plin2 may be involved
in neurodegeneration.
In order to obtain insight into the possible causal relationship
between Plin2 and IL-6, we took advantage of primary DF cultures
that are now considered a reliable model system to study metabolic
abnormalities related to neurodegenerative diseases [40, 41]. We
treated DFs with metformin, a glucose-lowering drug able to modu-
late lipid metabolism and inflammatory response [42–44]. Treatment
with 1 mM metformin for 48 h induced no change in the expression
of Plin2 in controls, a decrease in AD cases and an increase in cente-
narians (Figure 6B). Consistently, IL-6 expression followed the same
trend of Plin2 (Figure 6C), suggesting that Plin2 and IL-6 levels are
connected.
DISCUSSION
A number of studies have addressed the question of expression of
Plins in the brain [18, 45]; however, in most cases, these studies
focused either on Plins as LDs markers or on specific cell types or dis-
eases. Moreover, there is a general lack of knowledge on the age-
related variability in their expression. For example, a recent study
reported that the majority of LDs in the brain are found in the
microglia [34], whereas other studies showed the presence of LDs in a
tiny number of cells (the above-mentioned LLCs), in meningeal, corti-
cal and neurogenic brain regions [7]. However, considering that LDs
are almost universal organelles and lipid accumulation has been dem-
onstrated in both neurons and astrocytes in lesions [46], as well as in
GFAP+ cells that are closely associated to the ependymal niche [47],
it is likely that LDs are more widespread in the brain than previously
T AB L E 1 Spearman correlation analysis between interleukin-6
(IL-6) and perilipin (Plin)1, Plin2, Plin3, Plin4 and Plin5






Note: Significance level of p value is <0.05. n.s. = not significant;
ρ = Spearman rank correlation coefficient, rho. Plin2 is the only protein
significantly and positively correlated with IL-6 (shown in bold).
F I GU R E 6 Plin2 and IL-6 analysis. (A) Regression analysis of relative transcript values of Plin2 and IL-6 in frontal cortex samples from nine
control subjects (CTR), 10 early tauopathy (ET) patients, 15 Alzheimer’s disease (AD) patients and three centenarians (CENT). (B, C) Relative
transcript levels of (B) Plin2 and (C) IL-6 in dermal fibroblast cultures from five CTR, two AD and three CENT, with or without 1 mM metformin
for 48 h. Data are expressed as mean  SD. Student’s t test was applied
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thought and possibly differ in regard to the expression of PAT family
according to the specificities and needs of the cell type. In this study,
we have checked the expression pattern of all the members of the
PAT family in different areas and cell types of human brain, and we
included in the study autoptic samples from subjects of different ages,
with or without signs of neurodegeneration, in particular patients with
ET or AD. We showed that only Plin2, Plin3 and Plin5 are expressed
at the protein level and are expressed with variable intensity in differ-
ent brain areas. In particular, Plin2 appears expressed more in grey
matter and in neurons, in all the areas analysed (frontal and temporal
cortex, hippocampus and cerebellum, though in the latter, the expres-
sion is weaker), whereas Plin3 and Plin5 appear expressed more in
white matter. Moreover, Plin3 seems expressed more in astrocytes,
whereas Plin5 appears to be expressed in many cell types, including
oligodendrocytes. Interestingly, Plin2 is the only member of the PAT
family to be modulated by age or neurodegeneration.
The presence of LLCs has been reported to increase with age [7],
and more recently, Marschallinger et al. reported that microglia from
old animals and humans display elevated numbers of LDs [34]. In our
hands, samples from old people or from ET or AD patients showed
increased expression of Plin2, but not of Plin5, whereas Plin3
showed a trend to increase as well, especially in frontal cortex and
cerebellum, however, without reaching statistical significance. To
date, Plin2 (together with Plin3) has been adopted only as a marker
for the presence of LDs, but no one, to the best of our knowledge,
has investigated Plin2 and other PAT family members in order to
understand whether a possible shift in the expression level of Plins
does occur with age or disease. Our results suggest that Plin2 may be
correlated with advancing age and neurodegeneration. Of note, cente-
narians that represent examples of extreme longevity display Plin2
levels similar to those of 70- to 80-year-old people or patients with
low AD, indicating that the brain of these exceptional subjects are
likely to be younger than their chronological age, at least as far as LDs
accumulation, in agreement with epigenetic and proteomic data [48].
Interestingly, our data strongly suggest that Plin2 is also
expressed more in patients with either ET or AD. In particular, the fact
that Plin2 appears to be elevated in patients with low levels of neu-
rodegeneration, such as ET, suggests that it could be involved in the
early phases of the neurodegeneration. Actually, lipid accumulation
has been already reported in neurodegeneration [16, 49–51]; how-
ever, it is possible that lipids that accumulate in Plin2-expressing LDs
are more detrimental than others. This hypothesis should be tested by
future studies. However, it is known that Plin2 is associated not only
with LDs, and thus with intracellular accumulation of lipids, but also
with inflammation (reviewed in Farmer et al. [16]). In particular, it has
been demonstrated that the manipulation of Plin2 expression affects
pro-inflammatory parameters. As an example, the overexpression of
Plin2 in macrophages increases the mRNA levels and production
of IL-6, TNFα and MCP-1, whereas Plin2 knock-down has the oppo-
site effect [52]. Moreover, hepatic-specific knockout of Plin2 protec-
ted mice from high-fat diet induced steatosis and decreased the
expression of cyclo-oxygenase 2, IL-6, TNF-α and IL-1β [53]. In
another study, Plin2 knockout inhibited an LPS-induced inflammatory
response [54]. Therefore, the existence of a causal link between Plin2
accumulation and neuroinflammation is more than likely, and the data
presented here may suggest that the same Plin2-IL-6 link exists at
brain level and agrees with the hypothesis of the inflammatory origin
of neurodegenerative diseases. Indeed, here, we reported that the
expression of Plin2, but not other PAT family members, is associated
in the brain with the expression of IL-6. To further prove the link
between Plin2 and IL-6, we treated 10 DF lines from healthy controls,
AD patients and centenarians with metformin, a biguanide widely
F I GU R E 7 Schematic representation of the role of Plin2 in the brain considered as a continuum. We hypothesise that during aging and in
neurodegenerative diseases such as Alzheimer’s disease (AD), there is an accumulation of Plin2 (and consequently of Plin2-associated lipid
droplets [LDs]) that may lead to a concomitant (possibly causal) increase in the expression of IL-6. See text for details
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used as antidiabetic drug known to impact on lipid metabolism and
inflammation [44, 55, 56]. We observed three distinct responses to
metformin in terms of Plin2 transcript expression (no effect in healthy
controls, decreased expression in AD patients and increased expres-
sion in centenarians), and interestingly, the expression of IL-6, in the
same samples, always followed the same trend. As a whole, these data
are compatible with the hypothesis that there is a causal link between
Plin2 and inflammation. Further studies are needed to better clarify
the precise mechanisms for the differential responses observed in DF
lines, however, it has been reported that in different tissues, metfor-
min can have opposite effects on the expression of Plin2 [57, 58].
Our data support, though indirectly, the idea that in the brain
Plin2 plays a role in neuroinflammation and support the hypothesis
that neuroinflammation is an early event in the pathogenesis of neu-
rodegeneration [59, 60], where Plin2 may have a still unrecognised
role. Further studies are needed to prove this hypothesis.
In the important study of Marschallinger et al. [34], microglial cells
were reported to express both Plin2 and Plin3. However, these
authors did not report on markers for cell types other than Iba1,
TMEM119 or CD68, meaning that they limited their investigation to
microglial cells only. We report that some TMEM119+ cells do
express Plin2; however, our IHC analysis suggests that Plin2 and Plin3
are mostly expressed in neurons and astrocytes, respectively, but we
cannot exclude that these Plins can be expressed in other cell types.
Moreover, our analysis adds to the data by Marschallinger et al. [34],
indicating that Plin2, but not other PAT family members, seems to
accumulate with age and disease.
To summarise, our study indicates that Plins are widely expressed
in human brain, with some differences in the distribution among dif-
ferent areas, and especially between white and grey matter. However,
the most important finding is that Plin2 appears to be the only PAT
family member to be modulated with age and neuroinflammation.
Accordingly, we propose that lipid accumulation occurs physiologically
in the aging brain within Plin2-decorated LDs, and this accumulation
may be the initial inflammatory step toward neurodegeneration
(Figure 7). Furthermore, Plin2 may be a connection between brain
aging and inflammation. This hypothesis is also in agreement with the
more general one of a continuum between aging and age-related dis-
eases [61]. Some aspects remain unclear, including the precise role of
Plins in the lipid metabolism of different cell types (in particular, Plin3
and Plin5 that result strongly expressed at the level of the glial com-
partment), and warrant further studies.
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